CALC
CalciMedica, Inc. (CALC) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No 5-year revenue, EPS, or FCF CAGR is provided, so CALC lacks evidence of sustained compounding versus peers over a multi-year horizon.
TTM ROIC is deeply negative at -1.23, indicating current capital deployment is destroying value rather than funding scalable revenue expansion like stronger peers.
Capex-to-revenue is reported at zero, which suggests limited reinvestment capacity for growth initiatives compared with peers that can fund expansion internally.
The absence of segment concentration data prevents proof of repeatable cross-sell or platform scaling, leaving CALC with weaker visible growth drivers than diversified peers.
Market Tailwinds
No filing-based evidence shows CALC benefiting from durable demand tailwinds that would support multi-year revenue expansion relative to peers.
The provided metrics do not demonstrate addressable-market conversion, so growth appears less externally supported than peers with clearer structural demand capture.
Negative ROIC and negative interest coverage imply current operations are not translating market demand into scalable earnings growth as effectively as peers.
Without disclosed segment or geographic expansion data, CALC lacks visible tailwind breadth that would typically lift long-term growth capacity.
Scalability Expansion
Negative TTM ROIC and negative interest coverage indicate weak operating scalability, limiting CALC’s ability to compound revenue efficiently versus peers.
The cash conversion cycle is highly negative, but the metric is not accompanied by evidence of durable scaling, so it cannot anchor stronger growth capacity.
Net debt to EBITDA of 0.93 is manageable, yet leverage does not offset the absence of proven reinvestment-driven expansion versus stronger peers.
No evidence is provided for recurring revenue, network effects, or multi-product expansion, leaving CALC with limited structural scalability signals.
Constraints Limitations
Deeply negative ROIC is a structural constraint because it limits the company’s ability to reinvest profitably and sustain long-term revenue compounding.
Negative interest coverage suggests financing flexibility is constrained, which can cap expansion capacity relative to peers with stronger cash generation.
Missing historical growth and segment data create an evidence gap, but the available profitability metrics still point to impaired scaling capacity.
The combination of weak returns and limited reinvestment proof indicates CALC faces more structural growth constraints than most peers.
Overall Score
CALC shows weak 10-year growth potential because the available metrics provide no proof of sustained compounding, while negative ROIC and negative interest coverage constrain scalable expansion versus peers.
Score Driver: Negative Roic
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on CalciMedica, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
